City-Garage AG

St. Gallen

4 weeks ago

Leiter Verkauf 100% (m/w/d)

  • 21 March 2026
  • 100%
  • St. Gallen

Job summary

Join a groundbreaking PhD project in In Vitro Diagnostics at ETH Zurich! This is a unique opportunity to tackle MDR-MTB challenges and work in a dynamic environment.

Tasks

  • Develop CRISPR-Cas-based electrochemical biosensors for TB.
  • Conduct fieldwork and evaluate assays using patient samples.
  • Collaborate with an international team and manage project objectives.

Skills

  • Master’s degree in science or engineering; background in biosensing preferred.
  • Strong communication and collaboration skills.
  • Ability to focus on project objectives and deliverables.

Is this helpful?

About the job

PhD student in In Vitro Diagnostics, CRISPR–Cas / Electrochemistry100%, Zurich, fixed-termDr Daniel A. Richards and Professor Andrew J. deMello, in the Institute for Chemical and Bioengineering at ETH Zürich (ETHZ), and Dr Loïc Burr of the Swiss Center for Electronics and Microtechnology (CSEM), are searching for a PhD student to develop CRISPR–Cas-based electrochemical biosensors for multidrug resistant Mycobacterium tuberculosis (MDR-MTB). This work is funded as part of a SNSF BRIDGE Discovery grant, and you would work as part of a multiinstitutional consortium, including ETHZ, CSEM, the Swiss Tropical Public Health Institute (Swiss TPH), and the National Centre for Tuberculosis and Lung Disease (NCTLD) in Tblisi, Georgia. The position will ideally be filled by someone with a background in CRISPR–Cas and/or electrochemical biosensing, though anyone with experience in biosensing or analytical chemistry will be considered. This is a four-year position, and will include time at both ETHZ and CSEM.Project backgroundTuberculosis (TB) kills an estimated 1.25 million people each year, making it the single deadliest infectious disease. Unfortunately, TB disproportionately impacts low- and middle-income countries (LMICs); 98% of the global TB cases occur within LMICs, leading to devastating effects. Furthermore, the proliferation of this disease has resulted in widespread misuse of antibiotics, leading to the development of substantial drug resistance. Indeed, in the worst-affected regions, drug resistance among recurring TB infections has risen above 50%.Most TB deaths are preventable if diagnosed early. However, almost a quarter of all TB cases go undiagnosed. Similarly, the proliferation of drug resistance in TB can be partially attributed to a scarcity of effective methods for identifying resistance markers, which results in poor antibiotic stewardship. Unfortunately, contemporary diagnostic technologies have proved insufficient for diagnosing TB and associated drug resistances, particularly at the point-of-care (PoC). Few technologies exist that can quickly and accurately diagnose TB and simultaneously determine resistances, and those that can are large and expensive, precluding their use in LMICs. They are also overly reliant on sputum samples, which can be difficult to obtain, particularly in low-resource settings.In this PhD project, we aim to develop RPA–CRISPR–Cas assays capable of multiplexing 14 targets for TB and associated markers of drug resistance from a single sample. These assays will be combined with novel electrochemical reporters to facilitate miniaturization and provide quantitative readouts of disease. To facilitate deployment at the PoC, we will leverage the facilities and expertise of CSEM to integrate these technologies into a highly affordable cartridge & reader system. The research team will be supported by the Swiss Tropical and Public Health Institute and the National Center for Tuberculosis and Lung Disease in Georgia, who will validate the technology in patient samples and perform a small pilot study. This will provide the student with the opportunity to travel and perform fieldwork.These assays will fill a critical gap in the current treatment pathway of TB and bring care to millions of underserved patients, particularly in LMICs. By enabling rapid diagnosis of TB, this technology will facilitate more accurate and timely medical interventions, ultimately improving patient outcomes and decreasing the burdens on healthcare systems. Moreover, by focusing on common drug resistance markers, this technology will improve antimicrobial stewardship and be a valuable weapon in the fight against antimicrobial resistance (AMR).Job descriptionDevelop nucleic acid amplification tests (NAATs) and CRISPR–Cas assays specific for MTB and MDR–MTB Develop solid-phase electrochemical reporters for CRISPR–Cas assays Evaluate your developed assays using patient-derived samples Protein expression Work closely with our academic and industrial project partners to ensure the work progresses in line with the larger project objectives Contribute to project management, including financial and time management Present at internal project meetings and at international conferences Write peer-reviewed publications ProfileWe would like to hear from scientists who are keen to gain expertise in bioengineering, in vitro diagnostics, and global health. Candidates are expected to have obtained a Master’s degree in a relevant science or engineering discipline. However, candidates will be judged on their overall experience, expertise and ambitions, rather than on their specific research discipline(s). Successful candidates will be part of an international research team and are expected to be highly motivated and passionate about science, engineering and global health.You bring to the role:The ability to work well in a highly international, collaborative environment Ability to maintain focus on project objectives and deliverables Drive to take your research to an advanced technology readiness level Ability to work effectively with a range of collaborators Ability to write and communicate effectively and at a high level WorkplaceWorkplaceWe offerA multicultural and multidisciplinary research environment Attractive hiring conditions Access to state of the art equipment and resources Strong support in career progression We value diversity and sustainabilityCurious? So are we.We look forward to receiving your online application with the following documents:A cover letter detailing your motivation for applying, and how you meet the position requirements A detailed CV and details of at least two references Applications will be assessed continually, and a short list for interview will be drawn up mid February. Interviews will be held online shortly after. We anticipate the chosen candidate starting the project in 2026. Please note that we exclusively accept applications submitted through our online application portal. Applications via email or postal services will not be considered.Further information about the deMello group can be found on the website. Further information about CSEM can be found on their website. Questions regarding the position are welcome, and should be directed to Dr Daniel Richards (E-Mail schreiben) and Dr Loïc Burr (E-Mail schreiben).About ETH ZürichCurious? So are we.We look forward to receiving your online application with the following documents:A cover letter detailing your motivation for applying, and how you meet the position requirements A detailed CV and details of at least two references Applications will be assessed continually, and a short list for interview will be drawn up mid February. Interviews will be held online shortly after. We anticipate the chosen candidate starting the project in 2026. Please note that we exclusively accept applications submitted through our online application portal. Applications via email or postal services will not be considered.Further information about the deMello group can be found on the website. Further information about CSEM can be found on their website. Questions regarding the position are welcome, and should be directed to Dr Daniel Richards (E-Mail schreiben) and Dr Loïc Burr (E-Mail schreiben)

Categories:

Commercial / Sales

Salary estimator

Try our salary estimator to better understand what you can aim for as a Head of Sales

Salary for Head of Sales